Bridgewater, New Jersey
Kashiv BioSciences’ operates from a state-of-the-art 150,000 sq.ft. R&D and manufacturing facility with capabilities for the development of innovative platform technologies, specialty products, controlled substances (CII-V), and complex oral dosage forms. It is an FDA-registered site and complies fully with Local, State, and Federal Agencies, OSHA, DEA, EPA, and cGMP Standards.
cGMP Manufacturing Facility
Technicians operate a three-layer tablet press used for controlled release products
Corporate Headquarters and oral R&D and Manufacturing Site
PISCATAWAY, New Jersey
Kashiv BioSciences’ 50,000 sq. ft. R&D facility has capabilities for mammalian cell line development, advanced analytical characterization, bioassay development, and small-scale manufacturing of complex proteins and monoclonal antibodies.
Analytical Characterization Lab
Cell Line Process Development
Biosimilar R&D Facility
Kashiv BioSciences’ 100,000 sq.ft. R&D and manufacturing facility has capabilities for development and manufacturing of commercial-scale microbial cell lines, drug substance, and a fill and finish line for prefilled syringes and vials. It is an FDA-registered site and complies fully with Local, State, and Federal Agencies, OSHA, EPA, and cGMP Standards.
Upstream Production Suite
Injectable Fill and Finish Line
Biosimilar R&D and Injectable Manufacturing Facility
AHMEDABAD, GUJARAT, INDIA
Kashiv BioSciences’ 125,000 sq.ft. R&D facility contains state-of-the-art analytical labs for characterization, stability, bioassay development, process development, and small scale manufacturing of complex proteins for biosimilars. This site also conducts R&D for prodrugs and 505(b)(2) programs.
India office and R&D facility
Advanced analytical suites for biosimilar, 505(b)(2), and prodrug development
Analytical labs equipped with the latest technology